Fig. 5: F16BP MPs-based vaccines are compatible with adoptively transferred DCs and improve survival in melanoma.
From: Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice
a Kaplan–Meir curve demonstrating significantly higher survival of mice treated with adoptively transferred Vacc MPs (n = 10, p < 0.001), b Representative tumour images of different treatment groups on day 16. c Mice treated with adoptively transferred Vacc DCs had significantly lower tumour weights as compared to other treatment groups, in vivo (n = 3; One-way ANOVA Tukey’s test). d, e Significantly higher total, as well as activated DCs, were observed in mice treated with adoptively transferred Vacc DCs as compared to other treatment groups, in vivo (n = 4; One-way ANOVA Tukey’s test). f Significantly higher MHCI+ activated DCs were observed in mice treated with adoptively transferred Vacc DCs as compared to other treatment groups, in vivo (n = 4; One-way ANOVA Tukey’s test). g Significantly higher MHCII+ activated DCs were observed in mice treated with adoptively transferred Vacc DCs as compared to F16BP DCs, in vivo (n = 4; One-way ANOVA Tukey’s test). Data represented as mean ± std error.
